Valeria Gutowski Sells 1,258 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) CAO Valeria Gutowski sold 1,258 shares of Enfusion stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $8.17, for a total value of $10,277.86. Following the sale, the chief accounting officer now directly owns 35,599 shares in the company, valued at approximately $290,843.83. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Enfusion Stock Up 1.0 %

Shares of NYSE ENFN opened at $8.40 on Monday. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 277.43, a PEG ratio of 1.90 and a beta of 0.96. The stock’s fifty day simple moving average is $9.15 and its 200 day simple moving average is $9.10. Enfusion, Inc. has a 52-week low of $7.52 and a 52-week high of $11.56.

Enfusion (NYSE:ENFN) last issued its earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The company had revenue of $48.05 million during the quarter, compared to analyst estimates of $47.67 million. Enfusion had a return on equity of 6.60% and a net margin of 1.40%. During the same quarter in the previous year, the firm earned $0.04 earnings per share. As a group, analysts anticipate that Enfusion, Inc. will post 0.09 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ENFN. Bank of America lifted their price target on Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th. Morgan Stanley began coverage on Enfusion in a research report on Friday, May 10th. They set an “overweight” rating and a $11.00 price target on the stock. Finally, The Goldman Sachs Group cut Enfusion from a “neutral” rating to a “sell” rating and lowered their price target for the company from $9.00 to $8.00 in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.33.

Hedge Funds Weigh In On Enfusion

A number of hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new stake in shares of Enfusion in the first quarter worth $44,000. Tower Research Capital LLC TRC boosted its position in shares of Enfusion by 680.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock worth $96,000 after buying an additional 8,627 shares during the period. Barclays PLC boosted its position in shares of Enfusion by 29.0% in the third quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after buying an additional 2,430 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Enfusion in the first quarter worth $102,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Enfusion in the first quarter worth $109,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.